Recherche
Résultats 1-10 de 747
-
Inappropriate anticholinergic drugs prescriptions in older patients: analysing a hospital database
International Journal of Clinical Pharmacy, 02-2018, 40 (1), 94-100Article dans une revue scientifique -
Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059
BLOOD, 05-2017, 129 (20), 2808-2810Article dans une revue scientifique -
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Journal of clinical oncology, 2017, 35, 2473Article dans une revue scientifique -
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet (London, England), 2017Article dans une revue scientifique -
Eight Cycles of ABVD Versus Four Cycles of BEACOPP(escalated) Plus Four Cycles of BEACOPP(baseline) in Stage III to IV, International Prognostic Score >= 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
Journal of clinical oncology, 2016, 34, 2028-+Article dans une revue scientifique -
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Journal of clinical oncology, 2017, 35, 552Article dans une revue scientifique -
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients
Human pathology, 2017, 64, 128-136Article dans une revue scientifique -
Critical care admission following elective surgery was not associated with survival benefit: prospective analysis of data from 27 countries.
Intensive care medicine, 2017, 43, 971-979Article dans une revue scientifique -
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma
American journal of hematology, 2016, 91, 179-184Article dans une revue scientifique -
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Lancet Oncol., 2016, 17, 319-331Article dans une revue scientifique